AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
London close: Stocks slip as US jobless claims rise
20 February 2025 16:06
(Sharecast News) - London equities ended lower on Thursday as investors reacted to a higher-than-expected rise in US jobless claims and a decline in UK consumer confidence.
-
UBS ups rating on AstraZeneca to 'buy'
13 February 2025 11:18
(Sharecast News) - UBS has upgraded AstraZeneca to a 'buy', citing the London-listed pharmaceutical firm's "sector-leading" drug pipeline.
-
Morgan Stanley sees huge upside at AstraZeneca
12 February 2025 10:21
(Sharecast News) - Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to build positions at a "compelling entry point".
-
Revenues, profits surge at AstraZeneca
6 February 2025 08:00
(Sharecast News) - AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
-
AstraZeneca's Imfinzi set for go-ahead by EU to treat lung cancer
3 February 2025 07:02
(Sharecast News) - AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC)...
-
AstraZeneca's Enhertu gets new US approval
28 January 2025 07:03
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone...
-
AstraZeneca gets first US approval for cancer treatment Datroway
20 January 2025 07:30
(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan, a...
-
AstraZeneca's rare cancer drug Calquence gets US regulatory nod
17 January 2025 07:13
(Sharecast News) - AstraZeneca has announced that its Calquence drug has been approved in the US when used alongside chemoimmunotherapy for patients with previously untreated mantle cell lymphoma (MCL).
-
London close: Stocks mixed in quiet post-Christmas trade
27 December 2024 14:38
(Sharecast News) - London markets closed on a mixed note Friday in subdued trading, as the ongoing holiday period kept activity light with little news to influence sentiment.
-
AstraZeneca pulls EU application for cancer drug
24 December 2024 07:09
(Sharecast News) - AstraZeneca has pulled its European marketing authorisation application for its non-small cell lung cancer treatment based on the results of a phase III trial.
-
AstraZeneca lung cancer drug Tagrisso approved by EU regulators
23 December 2024 07:17
(Sharecast News) - AstraZeneca's lung cancer treatment Tagrisso has been approved by European Union regulators on the back of "powerful results" from a phase III trial.
-
AstraZeneca cancer drug secures US approval
5 December 2024 08:48
(Sharecast News) - AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the biopharmaceutical specialist confirmed on Thursday.
Company announcements Announcements
-
Filing of Form 20-F with SEC
19 February 2025 07:00
AstraZeneca
-
Holding(s) in Company
18 February 2025 14:00
AstraZeneca
-
Annual Financial Report
18 February 2025 11:00
AstraZeneca
-
Directorate Change
18 February 2025 07:00
AstraZeneca
-
Final Results
6 February 2025 07:00
AstraZeneca
-
Total Voting Rights
3 February 2025 17:00
AstraZeneca
-
Imfinzi recommended for EU approval for LS-SCLC
3 February 2025 07:00
AstraZeneca
-
Enhertu approved in US for breast cancer post ET
28 January 2025 07:00
AstraZeneca
-
Dato-DXd approved in US for HR+ breast cancer
20 January 2025 07:00
AstraZeneca
-
Calquence combination approved in US for 1L MCL
17 January 2025 07:00
AstraZeneca
-
Total Voting Rights
2 January 2025 15:00
AstraZeneca
-
Dato-DXd NSQ NSCLC application withdrawn in EU
24 December 2024 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.